Compare Torrent Pharma with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs IPCA LABS - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA IPCA LABS TORRENT PHARMA/
IPCA LABS
 
P/E (TTM) x 35.9 25.4 141.4% View Chart
P/BV x 7.8 5.4 144.2% View Chart
Dividend Yield % 1.3 0.4 325.9%  

Financials

 TORRENT PHARMA   IPCA LABS
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-21
IPCA LABS
Mar-21
TORRENT PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs3,0402,456 123.8%   
Low Rs1,9331,371 141.0%   
Sales per share (Unadj.) Rs473.0423.3 111.7%  
Earnings per share (Unadj.) Rs74.090.6 81.7%  
Cash flow per share (Unadj.) Rs112.9107.1 105.4%  
Dividends per share (Unadj.) Rs35.004.00 875.0%  
Avg Dividend yield %1.40.2 673.3%  
Book value per share (Unadj.) Rs344.9370.6 93.1%  
Shares outstanding (eoy) m169.22126.85 133.4%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x5.34.5 116.3%   
Avg P/E ratio x33.621.1 159.1%  
P/CF ratio (eoy) x22.017.9 123.3%  
Price / Book Value ratio x7.25.2 139.6%  
Dividend payout %47.34.4 1,071.2%   
Avg Mkt Cap Rs m420,798242,728 173.4%   
No. of employees `000NANA-   
Total wages/salary Rs m14,39610,136 142.0%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m80,04853,699 149.1%  
Other income Rs m7571,292 58.6%   
Total revenues Rs m80,80654,991 146.9%   
Gross profit Rs m24,66614,812 166.5%  
Depreciation Rs m6,5782,092 314.5%   
Interest Rs m3,583123 2,920.0%   
Profit before tax Rs m15,26313,890 109.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,7442,401 114.3%   
Profit after tax Rs m12,51911,488 109.0%  
Gross profit margin %30.827.6 111.7%  
Effective tax rate %18.017.3 104.0%   
Net profit margin %15.621.4 73.1%  
BALANCE SHEET DATA
Current assets Rs m55,23234,370 160.7%   
Current liabilities Rs m48,91611,331 431.7%   
Net working cap to sales %7.942.9 18.4%  
Current ratio x1.13.0 37.2%  
Inventory Days Days1449 29.5%  
Debtors Days Days76 125.9%  
Net fixed assets Rs m81,29826,295 309.2%   
Share capital Rs m846254 333.5%   
"Free" reserves Rs m57,52646,763 123.0%   
Net worth Rs m58,37247,017 124.2%   
Long term debt Rs m29,633365 8,109.7%   
Total assets Rs m136,53060,664 225.1%  
Interest coverage x5.3114.2 4.6%   
Debt to equity ratio x0.50 6,532.1%  
Sales to assets ratio x0.60.9 66.2%   
Return on assets %11.819.1 61.6%  
Return on equity %21.424.4 87.8%  
Return on capital %21.429.6 72.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m21,53927,172 79.3%   
Fx outflow Rs m7,1367,949 89.8%   
Net fx Rs m14,40319,223 74.9%   
CASH FLOW
From Operations Rs m20,10710,901 184.4%  
From Investments Rs m-4,494-5,207 86.3%  
From Financial Activity Rs m-16,561-3,058 541.5%  
Net Cashflow Rs m-8932,636 -33.9%  

Share Holding

Indian Promoters % 71.3 46.3 153.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 20.6 42.6 48.3%  
FIIs % 11.6 12.3 94.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 28.8 53.7 53.5%  
Shareholders   67,205 106,779 62.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   SUN PHARMA    LUPIN    CIPLA    AUROBINDO PHARMA    DR. REDDYS LAB    



Today's Market

Sensex Sheds 581 Points, Nifty Ends Near 17,100; HCL Tech & Tech Mahindra Top Losers(Closing)

Indian share markets witnessed negative trading activity throughout the day today and ended on a weak note.

Related Views on News

IPCA LABS 2020-21 Annual Report Analysis (Annual Result Update)

Sep 6, 2021 | Updated on Sep 6, 2021

Here's an analysis of the annual report of IPCA LABS for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of IPCA LABS. Also includes updates on the valuation of IPCA LABS.

IPCA LABS Announces Quarterly Results (1QFY22); Net Profit Down 30.8% (Quarterly Result Update)

Aug 9, 2021 | Updated on Aug 9, 2021

For the quarter ended June 2021, IPCA LABS has posted a net profit of Rs 3 bn (down 30.8% YoY). Sales on the other hand came in at Rs 16 bn (up 2.0% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

Sun Pharma vs Dr Reddy's: Which is Better? (Views On News)

Dec 16, 2021

In an extremely competitive market, two pharma companies are competing against each other to grab the top spot.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

More Views on News

Most Popular

These 5 Penny Stocks are Held by Rakesh Jhunjhunwala. Worth a Look?(Views On News)

Jan 18, 2022

Rakesh Jhunjhunwala is holding these penny stocks in his portfolio for several years now.

Time to Buy Energy Stocks(Fast Profits Daily)

Jan 14, 2022

Energy is a sector that looks set to take off. It's time to get in.

Tech Mahindra's CTC Acquisition: Too Expensive?(Views On News)

Jan 18, 2022

Tech Mahindra's acquisition of European IT-company fails to excite investors.

5 Hidden Tata Group Companies to Add to Your Watchlist(Views On News)

Jan 18, 2022

Here's all you need to know about these five Tata group stocks that aren't as popular as the others.

Insiders are Buying into these 6 Stocks Aggressively. More Details here...(Views On News)

Jan 19, 2022

While promoter holding is an important parameter, it should not be the sole reason for buying a stock.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Jan 27, 2022 03:36 PM

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 8-QTR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS